Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Dual Epicardial Endocardial Persistent Atrial Fibrillation(AF) Study (Staged DEEP) (Staged DEEP)

This study has been completed.
Information provided by (Responsible Party):
AtriCure, Inc. Identifier:
First received: July 11, 2012
Last updated: January 4, 2016
Last verified: January 2016

July 11, 2012
January 4, 2016
August 2012
December 2015   (Final data collection date for primary outcome measure)
  • Number of patients with pre-specified safety endpoints occurring in the first 30 days post-index procedure or hospital discharge, whichever is longer. [ Time Frame: 30 days post-index procedure or hospital discharge ]
  • Absence of atrial fibrillation [ Time Frame: 12 month follow-up ]
    Absence of atrial fibrillation (AF) at twelve month follow-up based on continuous 14 day ECG monitoring, while off all Class I and III antiarrhythmic therapy.
Same as current
Complete list of historical versions of study NCT01661205 on Archive Site
  • Number of Overall Serious Device or Procedure Related Adverse Event Rate [ Time Frame: 12 month follow-up ]
  • Number of subjects with Acute Procedure Success [ Time Frame: Day 0 ]
    Index procedure
  • Number of subject without atrial fibrillation [ Time Frame: 6 and 12 month follow-up ]
    AF free with or without the need of antiarrhythmic drugs
  • Number of Reinterventions [ Time Frame: 12 month follow-up ]
  • Number of DC cardioversion [ Time Frame: 12 month follow-up ]
  • Improvement in AF based on AF Symptoms Checklist Frequency and Severity Scores [ Time Frame: 12 month follow-up ]
    Improvement in AF Symptom Checklist Frequency and Severity Scores.
Same as current
Not Provided
Not Provided
Dual Epicardial Endocardial Persistent Atrial Fibrillation(AF) Study (Staged DEEP)
Feasibility Trial of a Staged Epicardial & Endocardial Approach for Treatment of Patients With Persistent or Long Standing Persistent Atrial Fibrillation With Radiofrequency Ablation
The purpose of this study is to assess the safety and technical feasibility of treating subjects with Persistent Atrial Fibrillation or Longstanding Persistent Atrial Fibrillation in a minimally invasive thoracoscopic ablation procedure utilizing the AtriCure Bipolar System, with mapping and additional lesion creation/ gap closure (as needed) provided by currently approved catheter technology, when the epicardial and endocardial phases are performed in a staged manner within 1-10 days apart, during the same hospitalization.
The purpose of this clinical investigation is to evaluate how safe a less invasive cardiac surgery using the AtriCure Bipolar System in conjunction with a catheter ablation procedure performed approximately 1-10 days after, in treating atrial fibrillation, and how effective is this staged procedure. The AtriCure Bipolar System will be used to perform the less invasive cardiac surgery and a standard electrophysiology catheter, currently available, will be used to perform the catheter ablation procedure. This surgical procedure is considered less invasive because it is done through tiny surgical punctures on the sides of the chest near the ribs instead of one large surgical incision of the breast bone to completely open the chest and access the heart, and it also avoids the need for the heart-lung bypass machine.
Phase 1
Phase 2
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Atrial Fibrillation
Device: Ablation procedure staged catheter ablation
AtriCure Bipolar System used in conjunction with a catheter ablation procedure performed 1-10 days apart
Experimental: AtriCure Bipolar System combined with a catheter ablation
Minimally invasive procedure using the AtriCure Bipolar System plus a catheter ablation performed approximately 1-10 days apart
Intervention: Device: Ablation procedure staged catheter ablation
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
December 2015
December 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age > 18 year
  • Patients with symptomatic persistent or longstanding persistent AF refractory to a minimum of one Class I or III AAD(s).
  • Patients with failed catheter ablation attempts are eligible if the patients are symptomatic with persistent or longstanding persistent AF. (catheter ablation procedure must be more than 3 months prior to index procedure)
  • Life expectancy of at least two years
  • Patient will and able to provide informed consent
  • Patient is willing and able to attend the scheduled follow-up visits

Exclusion Criteria:

  • Prior Cardiothoracic Surgery
  • Patient has NYHA Class IV heart failure
  • Evidence of underlying structural heart disease requiring surgical treatment
  • Surgical procedure within the 30 days prior to the index procedure
  • Ejection fraction < 30%
  • Measured left atrial diameter > 6.0 cm
  • Renal Failure
  • Stroke within previous 6 months
  • Known carotid artery stenosis greater than 80%
  • Evidence of significant active infection or endocarditis
  • Pregnant woman or women desiring to become pregnant in the next 24 months
  • Presence of thrombus in the left atrium determined by echocardiography
  • History of blood dyscrasia
  • Contraindication to anticoagulation, based on Investigator's opinion
  • Mural thrombus or tumor
  • Moderate to Severe COPD
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States,   Belgium,   Netherlands
Not Provided
Not Provided
Not Provided
AtriCure, Inc.
AtriCure, Inc.
Not Provided
Not Provided
AtriCure, Inc.
January 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP